OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Seymour on Patient Subsets That May Benefit From Curative FCR in CLL

September 21st 2023

John Seymour, MBBS, FRACP, PhD, discusses the characteristics of patient subgroups with chronic lymphocytic leukemia who may benefit from curative treatment with fludarabine, cyclophosphamide, and rituximab.

Dr Camidge on the Rationale for the TRUST-II Trial in ROS1+ NSCLC

September 20th 2023

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations.

Dr Park on the Rationale for the SYMPHONY-1 Trial in Relapsed/Refractory FL

September 20th 2023

Steven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.

Dr Liu on the 5-Year OS Data With Atezolizumab and Chemotherapy in ES-SCLC

September 20th 2023

Stephen V. Liu, MD, discusses the 5-year overall survival data with atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer.

Dr Chari on the Evolving Role of Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

September 20th 2023

Ajai Chari, MD, discusses the evolving role of bispecific antibodies and CAR T-cell therapies, such as ciltacabtagene autoleucel, in the treatment of patients with multiple myeloma.

Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FL

September 20th 2023

Tycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.

Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

September 20th 2023

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.

Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AML

September 20th 2023

Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.

Dr Pothuri on Treating Patients With Ovarian Cancer

September 19th 2023

Bhavana Pothuri, MD, discusses treatment considerations for patients in tough-to-treat subgroups of ovarian cancer based on currently available data.

Dr Nastoupil on the Use of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

September 19th 2023

Loretta J. Nastoupil, MD, discusses the rationale for investigating the use of lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Dr Phillips on Treatment With Bispecific Antibodies and CAR T-Cell Therapy in MCL

September 19th 2023

Tycel Phillips, MD, MPH, discusses treatment with bispecific antibodies and CAR T-cell therapy in patients with mantle cell lymphoma, and other non-Hodgkin lymphomas.

Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors

September 19th 2023

Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.

Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FL

September 19th 2023

Peter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.

Dr Hammers on Unmet Needs in the Frontline Treatment of RCC

September 18th 2023

Hans Hammers, MD, PhD, discusses areas of controversy and remaining unmet needs in the treatment of patients with renal cell carcinoma.

Dr Chari on Currently Available Bispecific Antibodies in Multiple Myeloma

September 18th 2023

Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.

Dr West on Adjuvant Endocrine Therapy Plus a CDK4/6 Inhibitor in Early-Stage Breast Cancer

September 18th 2023

Malinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.

Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC

September 18th 2023

Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.

Dr Luo on Optimal Initial Chemotherapy Regimens in NUT Carcinoma

September 18th 2023

Jia Luo, MD, discusses a retrospective analysis of initial chemotherapy regimens for the treatment of patients with locally advanced and metastatic NUT carcinoma, which was presented at the 2023 IASLC World Conference on Lung Cancer.

Dr Kuykendall on the FDA Approval of Momelotinib in Myelofibrosis

September 15th 2023

Andrew Kuykendall, MD, discusses the significance of the FDA approval of momelotinib in patients with myelofibrosis.

Dr Hwang on Considering AEs Associated With FDA-Approved Agents in Nonmetastatic Prostate Cancer

September 15th 2023

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.